Abstract:BACKGROUND: Breast cancer is the most common cancer among women, and radiotherapy plays a major role in its treatment. However, breast cancer radiotherapy can lead to incidental irradiation of the heart, resulting in an increased risk for a variety of heart diseases arising many years after radiotherapy. Therefore, identifying breast cancer patients at the highest risk for radiation-induced cardiac complications is crucial for developing strategies for primary and secondary prevention, which may contribute to healthy aging. There is still a need for precise knowledge on the relationship between radiation dose to specific cardiac structures and early subclinical cardiac changes and their occurrence over time that could finally lead to cardiac complications.OBJECTIVE: The MEDIRAD EARLY HEART study aims to identify and validate new cardiac imaging and circulating biomarkers of radiation-induced cardiovascular changes arising within first 2 years of breast cancer radiotherapy and to develop risk models integrating these biomarkers combined with precise dose metrics of cardiac structures based on three-dimensional dosimetry.METHODS: The EARLY HEART study is a multicenter, prospective cohort study in which 250 women treated for breast cancer and followed for 2 years after radiotherapy will be included. Women treated with radiotherapy without chemotherapy for a unilateral breast cancer and aged 40-75 years meet the inclusion criteria. Baseline and follow-up data include cardiac measurements based on two-dimensional speckle-tracking echocardiography, computed tomography coronary angiography, cardiac magnetic resonance imaging, and a wide panel of circulating biomarkers of cardiac injury. The absorbed dose will be evaluated globally for the heart and different substructures. Furthermore, the dose-response relationship will allow modeling the radiation-induced occurrence and evolution of subclinical cardiac lesions and biomarkers to develop prediction models.RESULTS: This study details the protocol of the MEDIRAD EARLY HEART study and presents the main limits and advantages of this international project. The inclusion of patients began in 2017. Preliminary results are expected to be published in 2019, and complete analysis should be published in 2021.CONCLUSIONS: The MEDIRAD EARLY HEART study will allow identifying the main cardiac imaging and blood-based determinants of radiation-induced cardiac injuries to better propose primary and secondary preventive measures in order to contribute to enhanced patient care and quality of life.TRIAL REGISTRATION: ClinicalTrials.gov NCT03297346; https://clinicaltrials.gov/ct2/show/NCT03297346 (Archived by WebCite at http://www.webcitation.org/72KS7MIUU).REGISTERED REPORT IDENTIFIER: RR1-10.2196/9906.

Population based audit of heart radiation doses in 6925 high-risk breast cancer patients from the Danish breast cancer group RT Nation study

Quality assessment of radiotherapy in the prospective randomized SENOMAC trial

Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer: results from a large population-based cohort

Assessing the Need for Adjusted Organ-at-Risk Planning Goals for Patients Undergoing Adjuvant Radiation Therapy for Locally Advanced Breast Cancer with Proton Radiation

Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer: Protocol for a European Multicenter Prospective Cohort Study (MEDIRAD EARLY HEART Study)

Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study)

Tangential Field Radiotherapy for Breast Cancer—The Dose to the Heart and Heart Subvolumes: What Structures Must Be Contoured in Future Clinical Trials?

The relationship between radiation doses to coronary arteries and location of coronary stenosis requiring intervention in breast cancer survivors

Cardiac dose-volume analysis of 9,411 patients with registry data for cardiovascular disease and overall survival.

Subclinical Left Ventricular Dysfunction Detected by Speckle-Tracking Echocardiography in Breast Cancer Patients Treated With Radiation Therapy: A Six-Month Follow-Up Analysis (MEDIRAD EARLY‐HEART study)

CT-planned internal mammary node radiotherapy in the DBCG-IMN study: benefit versus potentially harmful effects

Multi-centre evaluation of variation in cumulative dose assessment in reirradiation scenarios

Quality assurance of radiation therapy after breast-conserving surgery among patients in the BOOG 2013-08 trial

Were We Able to Reduce Cardiac Doses in Breast Cancer Radiotherapy Over Time?

Geriatric assessment with management for older patients with cancer receiving radiotherapy: a cluster-randomised controlled pilot study

Measuring dose in lung identifies peripheral tumour dose inaccuracy in SBRT audit

Treatment planning for patients with low rectal cancer in a multicenter prospective organ preservation study

Heart atlas for retrospective cardiac dosimetry: a multi-institutional study on interobserver contouring variations and their dosimetric impact

Risk of primary lung cancer after adjuvant radiotherapy in breast cancer—a large population-based study

Breast induration and irradiated volume in the DBCG HYPO trial: The impact of age, smoking, and boost

Effect of radiotherapy on coronary arteries and heart in breast-conserving surgery: a dosimetric analysis